A novel complement C3 inhibitor CP40-KK protects against experimental pulmonary arterial hypertension via an inflammasome NLRP3 associated pathway

Lei Dai,Yu Chen,Jinhua Wu,Zhen He,Yueqi Zhang,Wenjun Zhang,Yang Xie,Hesong Zeng,Xiaodan Zhong
DOI: https://doi.org/10.1186/s12967-023-04741-z
IF: 8.44
2024-02-18
Journal of Translational Medicine
Abstract:Pulmonary arterial hypertension (PAH) is a severe cardiopulmonary disease characterized by complement dependent and proinflammatory activation of macrophages. However, effective treatment for complement activation in PAH is lacking. We aimed to explore the effect and mechanism of CP40-KK (a newly identified analog of selective complement C3 inhibitor CP40) in the PAH model.
medicine, research & experimental
What problem does this paper attempt to address?